4 julio 2015
Patients with metastatic colorectal cancer (mCRC) that are mutation-free in the KRAS, NRAS, BRAF and PIK3CA genes showed significant benefit from continuing anti-epidermal growth factor receptor (EGFR) therapy beyond progression following first-line chemotherapy and an anti-EGFR monoclonal antibody, according to new study results.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/IIKvJGXlbCk/150704084339.htm
